Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is a small molecule chemical compound characterized by a tetrahydroisoquinoline ring system with chlorine substituents at the 7 and 8 positions. It acts as an inhibitor of phenylethanolamine N-methyltransferase (PNMT), an enzyme involved in catecholamine biosynthesis. This compound is used primarily in research related to psychiatric disorders and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. It has potential biological activity affecting central nervous system pathways relevant to these conditions[1][2][3]. The compound is for research use only and not approved for direct human use[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.